Table of Contents Author Guidelines Submit a Manuscript
International Journal of Hepatology
Volume 2013 (2013), Article ID 419302, 8 pages
http://dx.doi.org/10.1155/2013/419302
Review Article

The Role of Bridging Therapy in Hepatocellular Carcinoma

Department of Surgery, College of Medicine, University of Kentucky, Lexington, KY 40536-0293, USA

Received 16 March 2013; Revised 10 October 2013; Accepted 10 October 2013

Academic Editor: Daisuke Morioka

Copyright © 2013 Roberto Galuppo et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. http://www-dep.iarc.fr/, http://globocan.iarc.fr/factsheet.asp.
  2. V. Mazzaferro, E. Regalia, R. Doci et al., “Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis,” The New England Journal of Medicine, vol. 334, no. 11, pp. 693–699, 1996. View at Publisher · View at Google Scholar · View at Scopus
  3. V. Mazzaferro, Y. S. Chun, R. T. P. Poon et al., “Liver transplantation for hepatocellular carcinoma,” Annals of Surgical Oncology, vol. 15, no. 4, pp. 1001–1007, 2008. View at Publisher · View at Google Scholar
  4. P. P. McHugh, J. Gilbert, S. Vera, A. Koch, D. Ranjan, and R. Gedaly, “Alpha-fetoprotein and tumour size are associated with microvascular invasion in explanted livers of patients undergoing transplantation with hepatocellular carcinoma,” HPB, vol. 12, no. 1, pp. 56–61, 2010. View at Publisher · View at Google Scholar · View at Scopus
  5. J. M. Llovet, X. Mas, J. J. Aponte et al., “Cost effectiveness of adjuvant therapy for hepatocellular carcinoma during the waiting list for liver transplantation,” Gut, vol. 50, no. 1, pp. 123–128, 2002. View at Google Scholar · View at Scopus
  6. M. Cescon, A. Cucchetti, M. Ravaioli, and A. D. Pinna, “Hepatocellular carcinoma locoregional therapies for patients in the waiting list. Impact on transplantability and recurrence rate,” Journal of Hepatology, vol. 58, no. 3, pp. 609–618, 2013. View at Publisher · View at Google Scholar
  7. V. Mazzaferro, C. Battiston, S. Perrone et al., “Radiofrequency ablation of small hepatocellular carcinoma in cirrhotic patients awaiting liver transplantation: a prospective study,” Annals of Surgery, vol. 240, no. 5, pp. 900–909, 2004. View at Publisher · View at Google Scholar · View at Scopus
  8. D. Ansari and R. Andersson, “Radiofrequency ablation or percutaneous ethanol injection for the treatment of liver tumors,” World Journal of Gastroenterology, vol. 18, no. 10, pp. 1003–1008, 2012. View at Publisher · View at Google Scholar · View at Scopus
  9. R. Lencioni, L. Crocetti, P. De Simone, and F. Filipponi, “Loco-regional interventional treatment of hepatocellular carcinoma: techniques, outcomes, and future prospects,” Transplant International, vol. 23, no. 7, pp. 698–703, 2010. View at Publisher · View at Google Scholar · View at Scopus
  10. S. Bhoori, C. Sposito, A. Germini, J. Coppa, and V. Mazzaferro, “The challenges of liver transplantation for hepatocellular carcinoma on cirrhosis,” Transplant International, vol. 23, no. 7, pp. 712–722, 2010. View at Publisher · View at Google Scholar · View at Scopus
  11. A. Díaz-Sánchez, A. Matilla, O. Núñez et al., “Influence of treatment of hepatocellular carcinoma before liver transplantation on post transplant tumor recurrence and survival,” Journal of Gastroenterology and Hepatology, vol. 33, no. 3, pp. 155–164, 2010. View at Publisher · View at Google Scholar
  12. P. E. Majno, R. Adam, H. Bismuth et al., “Influence of preoperative transarterial lipiodol chemoembolization on resection and transplantation for hepatocellular carcinoma in patients with cirrhosis,” Annals of Surgery, vol. 226, no. 6, pp. 688–703, 1997. View at Publisher · View at Google Scholar · View at Scopus
  13. J. P. McGahan, P. D. Browning, J. M. Brock, and H. Tesluk, “Hepatic ablation using radiofrequency electrocautery,” Investigative Radiology, vol. 25, no. 3, pp. 267–270, 1990. View at Google Scholar · View at Scopus
  14. S.-F. Li, A. M. Hawxby, R. Kanagala, H. Wright, and A. Sebastian, “Liver transplantation for hepatocellular carcinoma: indications, bridge therapy and adjuvant therapy,” The Journal of the Oklahoma State Medical Association, vol. 105, no. 1, pp. 12–16, 2012. View at Google Scholar · View at Scopus
  15. R. J. Fontana, H. Hamidullah, H. Nghiem et al., “Percutaneous radiofrequency thermal ablation of hepatocellular carcinoma: a safe and effective bridge to liver transplantation,” Liver Transplantation, vol. 8, no. 12, pp. 1165–1174, 2002. View at Publisher · View at Google Scholar · View at Scopus
  16. P.-Y. Brillet, V. Paradis, G. Brancatelli et al., “Percutaneous radiofrequency ablation for hepatocellular carcinoma before liver transplantation: a prospective study with histopathologic comparison,” American Journal of Roentgenology, vol. 186, no. 5, pp. S296–S305, 2006. View at Publisher · View at Google Scholar · View at Scopus
  17. D. S. K. Lu, N. C. Yu, S. S. Raman et al., “Percutaneous radiofrequency ablation of hepatocellular carcinoma as a bridge to liver transplantation,” Hepatology, vol. 41, no. 5, pp. 1130–1137, 2005. View at Publisher · View at Google Scholar · View at Scopus
  18. F. Y. Yao, M. Kinkhabwala, J. M. LaBerge et al., “The impact of pre-operative loco-regional therapy on outcome after liver transplantation for hepatocellular carcinoma,” American Journal of Transplantation, vol. 5, no. 4, pp. 795–804, 2005. View at Publisher · View at Google Scholar · View at Scopus
  19. A. Bharat, D. B. Brown, J. S. Crippin et al., “Pre-liver transplantation locoregional adjuvant therapy for hepatocellular carcinoma as a strategy to improve longterm survival,” Journal of the American College of Surgeons, vol. 203, no. 4, pp. 411–420, 2006. View at Publisher · View at Google Scholar · View at Scopus
  20. J. M. Llovet, M. Schwartz, and V. Mazzaferro, “Resection and liver transplantation for hepatocellular carcinoma,” Seminars in Liver Disease, vol. 25, no. 2, pp. 181–200, 2005. View at Publisher · View at Google Scholar · View at Scopus
  21. D. S. Lu, N. C. Yu, S. S. Raman et al., “Percutaneous radiofrequency ablation of hepatocellular carcinoma as a bridge to liver transplantation,” Hepatology, vol. 41, no. 5, pp. 1130–1137, 2005. View at Google Scholar
  22. European Association for the Study of the Liver and European Organisation for Research and Treatment of Cancer, “EASL—EORTC clinical practice guidelines: management of hepatocellular carcinoma,” Journal of Hepatology, vol. 56, no. 4, pp. 908–943, 2012. View at Publisher · View at Google Scholar
  23. K. P. Charpentier, “Irreversible electroporation for the ablation of liver tumors: are we there yet?” Archives of Surgery, vol. 147, no. 11, pp. 1053–1061, 2012. View at Publisher · View at Google Scholar
  24. L. Marelli, R. Stigliano, C. Triantos et al., “Transarterial therapy for hepatocellular carcinoma: which technique is more effective? a systematic review of cohort and randomized studies,” CardioVascular and Interventional Radiology, vol. 30, no. 1, pp. 6–25, 2007. View at Publisher · View at Google Scholar · View at Scopus
  25. J. M. Llovet and J. Bruix, “Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival,” Hepatology, vol. 37, no. 2, pp. 429–442, 2003. View at Publisher · View at Google Scholar · View at Scopus
  26. J. Petersen, B. Henninger, B. Glodny, and W. Jaschke, “Transarterial chemoembolisation in hepatocellular carcinoma,” Wiener Medizinische Wochenschrift, vol. 163, no. 5–6, pp. 123–127, 2013. View at Publisher · View at Google Scholar
  27. Z. W. Peng, Y. J. Zhang, M. S. Chen et al., “Radiofrequency ablation with or without transcatheter arterial chemoembolization in the treatment of hepatocellular carcinoma: a prospective randomized trial,” Journal of Clinical Oncology, vol. 31, no. 4, pp. 426–432, 2013. View at Publisher · View at Google Scholar
  28. R. J. Lewandowski, L. M. Kulik, A. Riaz et al., “A comparative analysis of transarterial downstaging for hepatocellular carcinoma: chemoembolization versus radioembolization,” American Journal of Transplantation, vol. 9, no. 8, pp. 1920–1928, 2009. View at Publisher · View at Google Scholar · View at Scopus
  29. C. Toso, G. Mentha, N. M. Kneteman, and P. Majno, “The place of downstaging for hepatocellular carcinoma,” Journal of Hepatology, vol. 52, no. 6, pp. 930–936, 2010. View at Publisher · View at Google Scholar · View at Scopus
  30. M. Makuuchi, T. Kosuge, T. Takayama et al., “Surgery for small liver cancers,” Seminars in Surgical Oncology, vol. 9, no. 4, pp. 298–304, 1993. View at Google Scholar · View at Scopus
  31. J. Bruix, A. Castells, J. Bosch et al., “Surgical resection of hepatocellular carcinoma in cirrhotic patients: prognostic value of preoperative portal pressure,” Gastroenterology, vol. 111, no. 4, pp. 1018–1022, 1996. View at Google Scholar · View at Scopus
  32. T. Ishizawa, K. Hasegawa, T. Aoki et al., “Neither multiple tumors nor portal hypertension are surgical contraindications for hepatocellular carcinoma,” Gastroenterology, vol. 134, no. 7, pp. 1908–1916, 2008. View at Publisher · View at Google Scholar · View at Scopus
  33. W. Bleibel, S. H. Caldwell, M. P. Curry, and P. G. Northup, “Peripheral platelet count correlates with liver atrophy and predicts long-term mortality on the liver transplant waiting list,” Transplant International, vol. 26, no. 4, pp. 435–442, 2013. View at Publisher · View at Google Scholar
  34. J. Belghiti, “Resection and liver transplantation for HCC,” Journal of Gastroenterology, vol. 44, supplement 19, pp. 132–135, 2009. View at Publisher · View at Google Scholar · View at Scopus
  35. M. Ravaioli, G. L. Grazi, F. Piscaglia et al., “Liver transplantation for hepatocellular carcinoma: results of down-staging in patients initially outside the Milan selection criteria,” American Journal of Transplantation, vol. 8, no. 12, pp. 2547–2557, 2008. View at Publisher · View at Google Scholar · View at Scopus
  36. W. C. Chapman, M. B. Majella Doyle, J. E. Stuart et al., “Outcomes of neoadjuvant transarterial chemoembolization to downstage hepatocellular carcinoma before liver transplantation,” Annals of Surgery, vol. 248, no. 4, pp. 617–624, 2008. View at Publisher · View at Google Scholar · View at Scopus
  37. F. Y. Yao, R. K. Kerlan Jr., R. Hirose et al., “Excellent outcome following down-staging of hepatocellular carcinoma prior to liver transplantation: an intention-to-treat analysis,” Hepatology, vol. 48, no. 3, pp. 819–827, 2008. View at Publisher · View at Google Scholar · View at Scopus
  38. J. M. Llovet, J. Fuster, and J. Bruix, “The Barcelona approach: diagnosis, staging, and treatment of hepatocellular carcinoma,” Liver Transplantation, vol. 10, no. 2, pp. S115–S120, 2004. View at Google Scholar · View at Scopus
  39. L. Barbara, G. Benzi, S. Gaiani et al., “Natural history of small untreated hepatocellular carcinoma in cirrhosis: a multivariate analysis of prognostic factors of tumor growth rate and patient survival,” Hepatology, vol. 16, no. 1, pp. 132–137, 1992. View at Publisher · View at Google Scholar · View at Scopus
  40. J. Bruix, M. Sherman, J. M. Llovet et al., “Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference,” Journal of Hepatology, vol. 35, no. 3, pp. 421–430, 2001. View at Publisher · View at Google Scholar · View at Scopus
  41. J. Bruix and M. Sherman, “Management of hepatocellular carcinoma,” Hepatology, vol. 42, no. 5, pp. 1208–1236, 2005. View at Publisher · View at Google Scholar · View at Scopus
  42. B. E. Van Beers, C. M. Pastor, and H. K. Hussain, “Primovist, Eovist: what to expect?” Journal of Hepatology, vol. 57, no. 2, pp. 421–429, 2012. View at Publisher · View at Google Scholar
  43. T. Inoue, M. Kudo, M. Komuta et al., “Assessment of Gd-EOB-DTPA-enhanced MRI for HCC and dysplastic nodules and comparison of detection sensitivity versus MDCT,” Journal of Gastroenterology, vol. 47, no. 9, pp. 1036–1047, 2012. View at Publisher · View at Google Scholar · View at Scopus
  44. J. M. Llovet, M. Schwartz, and V. Mazzaferro, “Resection and liver transplantation for hepatocellular carcinoma,” Seminars in Liver Disease, vol. 25, no. 2, pp. 181–200, 2005. View at Publisher · View at Google Scholar · View at Scopus
  45. J. P. Duffy, A. Vardanian, E. Benjamin et al., “Liver transplantation criteria for hepatocellular carcinoma should be expanded: a 22-year experience with 467 patients at UCLA,” Annals of Surgery, vol. 246, no. 3, pp. 502–509, 2007. View at Publisher · View at Google Scholar · View at Scopus
  46. J. W. Marsh, I. Dvorchik, C. A. Bonham, and S. Iwatsuki, “Is the pathologic TNM staging system for patients with hepatoma predictive of outcome?” Cancer, vol. 88, no. 3, pp. 538–543, 2000. View at Google Scholar
  47. F. Y. Yao, N. M. Bass, B. Nikolai et al., “Liver transplantation for hepatocellular carcinoma: analysis of survival according to the intention-to-treat principle and dropout from the waiting list,” Liver Transplantation, vol. 8, no. 10, pp. 873–883, 2002. View at Publisher · View at Google Scholar · View at Scopus
  48. X. Yi, S. Yu, and Y. Bao, “Alpha-fetoprotein-L3 in hepatocellular carcinoma: a meta-analysis,” Clinica Chimica Acta, vol. 425, pp. 212–220, 2013. View at Publisher · View at Google Scholar
  49. F. A. Durazo, L. M. Blatt, W. G. Corey et al., “Des-γ-carboxyprothrombin, α-fetoprotein and AFP-L3 in patients with chronic hepatitis, cirrhosis and hepatocellular carcinoma,” Journal of Gastroenterology and Hepatology, vol. 23, no. 10, pp. 1541–1548, 2008. View at Publisher · View at Google Scholar · View at Scopus
  50. C. Duvoux, F. Roudot-Thoraval, T. Decaens et al., “Liver transplantation for hepatocellular carcinoma: a model including α-fetoprotein improves the performance of Milan criteria,” Gastroenterology, vol. 143, no. 4, pp. 986–994, 2012. View at Publisher · View at Google Scholar
  51. M. Berenguer, “Systematic review of the treatment of established recurrent hepatitis C with pegylated interferon in combination with ribavirin,” Journal of Hepatology, vol. 49, no. 2, pp. 274–287, 2008. View at Publisher · View at Google Scholar · View at Scopus
  52. C. S. Wang, H. H. Ko, E. M. Yoshida, C. A. Marra, and K. Richardson, “Interferon-based combination anti-viral therapy for hepatitis C virus after liver transplantation: a review and quantitative analysis,” American Journal of Transplantation, vol. 6, no. 7, pp. 1586–1599, 2006. View at Publisher · View at Google Scholar · View at Scopus
  53. E. Xirouchakis, C. Triantos, P. Manousou et al., “Pegylated-interferon and ribavirin in liver transplant candidates and recipients with HCV cirrhosis: systematic review and meta-analysis of prospective controlled studies,” Journal of Viral Hepatitis, vol. 15, no. 10, pp. 699–709, 2008. View at Publisher · View at Google Scholar · View at Scopus
  54. E. C. Verna, J. R. Burton, J. G. O'Leary et al., “Multicenter study of protease inhibitor-triple therapy in HCV-infected liver transplant recipients: report from the crush-C group,” Journal of Hepatology, vol. 58, supplement 1, pp. S10–S11, 2013. View at Publisher · View at Google Scholar
  55. P. Majno, R. Lencioni, F. Mornex, N. Girard, R. T. Poon, and D. Cherqui, “Is the treatment of hepatocellular carcinoma on the waiting list necessary?” Liver Transplantation, vol. 17, no. S2, pp. S98–S108, 2011. View at Publisher · View at Google Scholar · View at Scopus
  56. O. B. Lao, J. Weissman, and J. D. Perkins, “Pre-transplant therapy for hepatocellular carcinoma is associated with a lower recurrence after liver transplantation,” Clinical Transplantation, vol. 23, no. 6, pp. 874–881, 2009. View at Publisher · View at Google Scholar · View at Scopus